Peptides are having a moment. BPC-157 ("the Wolverine peptide"), TB-500, KPV, MOTS-C, Semax, Epitalon — names that were once confined to research labs are now podcast staples and wellness-clinic menu items. In July 2026, an FDA advisory committee voted to let compounding pharmacies expand access to several of these injectable peptides, even as some of the agency's own scientists raised objections. Interest is surging faster than the evidence is catching up.
That gap between hype and proof is worth understanding — and it's also a useful lens for looking at a very different, much older class of molecules that CellBB is built from: bioactive phospholipids. Peptides and phospholipids aren't competitors, exactly. They're two different classes of molecules converging on the same real estate: the cell membrane. Understanding how they differ — and where they might genuinely complement each other — says a lot about what each can realistically deliver right now.
What Peptides Actually Are, and Why the Excitement Is Real
Peptides are short chains of amino acids — smaller than proteins, but built from the same building blocks and capping out around 50 amino acids before they're classified as a protein instead. The body runs on them: more than 7,000 distinct peptides act as messengers, signaling molecules, growth factors, and regulators throughout human physiology. Insulin is a peptide. GLP-1 — the hormone class behind Ozempic, Wegovy, and Zepbound — is a peptide. Erythropoietin (EPO), the hormone that regulates red blood cell production, is also a peptide.
That track record is exactly why the current wave of interest isn't irrational. Peptides have produced some of the most successful drugs in modern medicine. The problem is that the peptides generating the most buzz right now — BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and others under FDA review — are nothing like insulin or GLP-1 in terms of evidence. Those approved drugs went through full randomized, placebo-controlled human trials. The trending wellness peptides mostly haven't. As Dr. Rachel Frank, an orthopedic surgeon and U.S. Soccer team physician, put it in a recent UCHealth interview: "Promising and proven are not the same thing."
The Peptide Problem: Getting There Intact
Here's the physical challenge peptides share, regardless of how promising the underlying signal might be: they're fragile. A chain of amino acids folded into a specific shape is easily broken down — by stomach acid, by digestive enzymes, by the same protein-degrading machinery the body uses on the food you eat. That's why almost all of the peptides generating buzz right now are injected rather than swallowed. And injection creates its own problem: it bypasses the gut's natural filtering and regulatory defenses entirely, delivering material directly into circulation with far less of the body's built-in quality control.
Dr. Jack Spittler, a sports medicine physician quoted alongside Dr. Frank, laid out three concerns that go beyond basic pharmacology:
- Delivery bypasses the body's defenses. Injecting something skips the GI tract's natural regulation of what actually gets absorbed.
- Sourcing and purity are largely unverified. Most of these peptides aren't FDA-regulated, and products purchased online — domestic or overseas — often come with no meaningful assurance of purity. Heavy metals, undisclosed additives, or mislabeled contents are a real risk.
- They're marketed as cure-alls. BPC-157 alone is promoted for ulcer healing, tendon repair, nerve regeneration, and neurodegeneration protection — a breadth of claims no single compound is likely to support.
Frank's list of what she'd want before recommending peptides to patients is a useful checklist for evaluating any of them: randomized, placebo-controlled human trials for specific conditions; standardized, independently verified manufacturing; clear dosing and delivery protocols; well-defined outcome measures; and real safety monitoring. Right now, most trending peptides check none of these boxes.
Where Phospholipids Occupy a Fundamentally Different Position
This is where the comparison gets interesting, because phospholipids and peptides aren't just different molecules — they play different roles at the cell membrane, though the roles overlap more than you'd expect.
A peptide is typically a messenger trying to reach a target — a receptor sitting on or inside a membrane, which it has to cross intact to deliver its signal. The membrane is usually an obstacle in its path.
A phospholipid is, first and foremost, structural — phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, and phosphatidylserine are literally the material the membrane is built from, the "bricks" that give it shape, flexibility, and integrity. But phospholipids don't stop at being building material. Several of them, and the molecules the cell cleaves from them, do the same kind of signaling work peptides specialize in: phosphatidylinositol gets phosphorylated into PIP2 and PIP3, the switches that gate some of the cell's most important internal signaling cascades; diacylglycerol and phosphatidic acid act as second messengers in their own right; sphingomyelin's breakdown products, ceramide and sphingosine-1-phosphate, regulate cell survival and direct immune cell trafficking; and lysophospholipids bind their own dedicated cell-surface receptors, functioning as signaling ligands much like a peptide hormone would. This is the real overlap between the two molecule classes — it's not just "phospholipids build walls, peptides send messages." Phospholipids do some of both.
What phospholipids don't generally do is act as long-range, receptor-specific messengers the way a hormone-like peptide (insulin, GLP-1, EPO) does — that precision signaling role is still where peptides specialize. But the idea that phospholipids are purely passive structural material undersells them. They're structural first, and they're active participants in the cell's communication network on top of that — which is part of why disrupting phospholipid balance has effects that ripple well beyond membrane stiffness.
That structural role is also why the safety profile looks so different. CellBB's bioactive phospholipids (BAP) are food-derived — sourced from egg yolk, a category with GRAS (Generally Recognized As Safe) standing and a food-safety history that predates modern supplement regulation entirely. On top of that food-grade foundation, CellBB's specific mechanism — a measurable increase in Natural Killer (NK) cell activity against tumor cells, isolated in laboratory testing to the concentration of a specific bioactive phospholipid, GPC-182 — has been studied for over 25 years of clinical use in Europe, under the Ovosan lineage CellBB descends from. That's a genuinely rare position for anything in the supplement aisle to occupy: a defined bioactive mechanism with decades of accumulated clinical use behind the base ingredient category, not compounded from scratch by a specialty pharmacy with an unverified supply chain.
Where the Two Could Actually Meet: Liposomal Peptide Delivery
Here's where this stops being a contrast and becomes a genuinely interesting possibility. Liposomes — the delivery vehicle CellBB already uses — are built from phospholipids. And it turns out that liposomal and lipid-based encapsulation is one of the most actively researched strategies in pharmaceutical science specifically for solving the peptide fragility problem described above.
The research is real, if still largely at the animal-study stage rather than large human trials — worth being just as honest about as we are about anything else in this space:
- Liraglutide (a GLP-1 peptide). Encapsulating liraglutide in specialized liposomes has been shown in animal studies to substantially improve its bioavailability relative to the free peptide given orally — in one formulation, researchers reported oral bioavailability reaching roughly half of what an intravenous dose achieves, a dramatic improvement over free peptide taken by mouth.
- Octreotide and human growth hormone. Liposomal carriers using specialized archaeal lipids have shown multi-fold increases in oral bioavailability for both peptides in rat studies compared to the unprotected drug.
- Exenatide (another GLP-1-class peptide). Liposomal formulations have demonstrated substantially improved oral bioavailability compared to free peptide alone in animal models, though still modest relative to injection — illustrating that the carrier has to be engineered specifically around each peptide, not treated as a universal fix.
The pattern across this research is consistent: a phospholipid-based capsule can shield a fragile peptide through the stomach, protect it from enzymatic breakdown, and meaningfully increase how much reaches circulation intact. It's not science fiction — it's an active, serious area of pharmaceutical research. It's also, like the peptide field itself, still working through the translation from animal models to reliable human outcomes.
Why This Doesn't Mean "Phospholipids Make Peptides Safe"
This is the point worth being precise about, because it would be easy to overstate: improving delivery is not the same as proving safety or efficacy.
CellBB's bioactive phospholipids have their own, separately established safety profile — GRAS status, decades of food and clinical use, a specific and published mechanism. That safety record belongs to the phospholipid carrier. It does not automatically transfer to whatever peptide might someday be paired with it. If BPC-157 or TB-500 were packaged in a liposome tomorrow, the liposome might solve the delivery problem — but the underlying questions Dr. Frank and Dr. Spittler raised about those specific peptides (real human trial data, standardized dosing, verified purity, established safety monitoring) would still be completely unanswered. Better delivery doesn't retroactively validate a payload that hasn't been through the clinical evidence process.
That distinction is exactly the one the peptide field itself is currently missing, and it's the one we think is worth modeling clearly: know which part of the story is proven, and which part is still a hypothesis.
The Bigger Picture
Phospholipids and peptides are genuinely different classes of molecule, at genuinely different points in their evidentiary life cycle. Bioactive phospholipids — the kind used in CellBB — carry a food-safety pedigree and a specific, clinically documented mechanism refined over 25 years. Most of today's trending wellness peptides are, in Dr. Spittler's words, "the Wild West" — biologically plausible, occasionally backed by compelling animal data, but largely unproven in rigorous human trials and inconsistently sourced.
Where the two genuinely intersect is delivery: the same phospholipid chemistry that builds a healthy cell membrane also builds the liposomal carriers that pharmaceutical researchers are using to try to get fragile peptides where they need to go intact. That's a real and active area of science, worth watching closely — but it solves a transportation problem, not a proof problem. As peptide research matures and (hopefully) catches up to the current hype, phospholipid-based delivery may end up playing a meaningful supporting role. For now, the honest distinction is the useful one: one class of molecule has decades of safety data behind it; the other is asking to be trusted on the strength of promise alone.
Sources: Neff T. "Peptides: Doctors explain the benefits, risks and FDA concerns." UCHealth Today, July 24, 2026. — Cui J, et al. "Recent Advances in Oral Peptide or Protein-Based Drug Liposomes." Pharmaceuticals. 2022. — Uhl P, et al. "Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide." Nanomedicine: Nanotechnology, Biology and Medicine. 2020. — Parmentier J, et al. "Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole." J Pharm Sci. 2014.